Primary pericardial mesothelioma is an extremely rare and aggressive malignant tumor originating from the mesothelial cells of the pericardium. It accounts for only 0.7-1% of all mesotheliomas (pleural mesothelioma is far more common). Annual incidence is less than 1 per million. Mean age at diagnosis is 50-70, and it is 2-3 times more common in males. Association with asbestos exposure is weaker than pleural mesothelioma (no exposure history in 50%). The tumor spreads diffusely along pericardial surfaces, encasing the heart like an envelope, creating both constrictive physiology and hemorrhagic effusion. On CT and MRI, nodular/irregular pericardial thickening, hemorrhagic effusion, and intense irregular enhancement are typical. Prognosis is extremely poor — median survival is 6-12 months from diagnosis. Most cases are detected at advanced stage and curative surgery is rarely possible.
Age Range
40-75
Peak Age
60
Gender
Equal
Prevalence
Rare
Pericardial mesothelioma originates from mesothelial cells lining the visceral or parietal pericardium. Although pathogenesis is not fully understood, the role of asbestos fibers is discussed similarly to pleural mesothelioma — however, no asbestos exposure history exists in 50% of cases. Alternative etiological factors: chronic pericardial inflammation, radiation, SV40 virus infection. Histologically three subtypes exist: epithelioid (50-70%, best prognosis), sarcomatoid (10-20%, worst prognosis), and biphasic (20-30%). The pathophysiological basis of imaging findings: nodular pericardial thickening reflects implantation of tumor cells along pericardial surfaces and nodular mass formation originating from mesothelium. Hemorrhagic effusion occurs due to vascular invasion by the tumor and leakage from fragile neovascular vessels — presence of red blood cells in pericardial fluid appears as high density (>25 HU) on CT and T1 hyperintensity on MRI. Intense and irregular enhancement reflects the tumor's rich neovascularization — VEGF expression is increased, creating an irregular, permeable capillary network. Diffuse pericardial involvement mimics constrictive physiology as it mechanically restricts the heart.
The combination of nodular and irregular pericardial thickening encasing the heart (with intense enhancement) + high-density hemorrhagic pericardial effusion (>25 HU) on CT is the most characteristic imaging finding for pericardial mesothelioma. This combination is critical for differentiation from benign pericardial diseases (constrictive pericarditis: homogeneous thickening + calcification, effusion: low-density transudate) and pericardial metastasis (usually focal, known primary malignancy). Diffuse distribution of nodular thickening along all pericardial surfaces reflects the implantation-type spread originating from mesothelium.
On non-contrast CT, pericardial mesothelioma appears as nodular and irregular pericardial thickening — may be focal or diffuse, thickness usually ranges from 5-30 mm. Pericardial effusion frequently accompanies and shows high density (>25 HU) — hemorrhagic content. Tumor nodules are at soft tissue density (30-50 HU). Calcification is rare (unlike constrictive pericarditis). In advanced cases, the tumor may invade mediastinal structures, myocardium, lungs, or diaphragm. Accompanying pleural effusion and pleural nodular thickening suggest contiguous pleural spread.
Report Sentence
On CT, nodular/irregular thickening along the pericardium (maximum ___ mm) is observed, accompanied by high-density pericardial effusion (___ HU); consistent with pericardial malignancy (mesothelioma).
On contrast-enhanced CT (arterial phase), pericardial tumor nodules show intense and irregular enhancement — this finding is the most critical feature for differentiation from benign pericardial thickening (minimal/homogeneous enhancement). Enhancement pattern is heterogeneous — solid tumor components enhance intensely while necrotic/cystic areas do not enhance. Pericardial effusion does not enhance. Tumor invasion into myocardium can be seen as irregular enhancement extending from subepicardial to subendocardial myocardium. Encasement of coronary arteries by tumor should be evaluated — critical for surgical planning.
Report Sentence
On contrast-enhanced CT, pericardial masses show intense and irregular enhancement with non-enhancing necrotic areas; consistent with malignant pericardial neoplasm (mesothelioma).
On T1-weighted MRI, pericardial mesothelioma appears as nodular pericardial masses showing iso-to-mildly hyperintense signal. Hemorrhagic effusion is characteristically T1 hyperintense — methemoglobin content creates T1 shortening. This combination (nodular pericardial mass + T1 hyperintense effusion) is highly suspicious for pericardial malignancy. Differentiation of tumor nodules from myocardium may be difficult on T1 because signal intensities are similar — contrast-enhanced sequences and cine images improve this distinction. Fat-suppressed T1 sequence distinguishes tumor from epicardial fat.
Report Sentence
On T1-weighted MRI, nodular masses showing isointense-to-mildly hyperintense signal are observed along the pericardium, accompanied by T1 hyperintense pericardial effusion (hemorrhagic); suggesting pericardial malignancy.
On T2-weighted images, pericardial mesothelioma appears as heterogeneous, intermediate-to-high signal intensity. Solid tumor components are mildly-to-moderately hyperintense, necrotic/cystic areas are markedly hyperintense. Hemorrhagic effusion shows variable T2 signal — low signal in acute hemorrhage (deoxyhemoglobin T2* effect), mixed signal in subacute-chronic hemorrhage (methemoglobin + hemosiderin). STIR (Short Tau Inversion Recovery) sequence increases tumor-to-tissue contrast and improves detection of small pericardial nodules by suppressing fat signal.
Report Sentence
On T2-weighted images, nodular masses showing heterogeneous signal are observed along the pericardium, with pericardial effusion showing variable signal intensity (hemorrhagic content).
On LGE sequences, pericardial mesothelioma shows intense and heterogeneous late gadolinium enhancement — this finding reflects the tumor's vascularity and areas of necrosis. Enhancing solid tumor components appear bright, necrotic/cystic areas appear dark. LGE is the best sequence for demonstrating tumor extent and degree of myocardial invasion — abnormal LGE in the myocardium suggests tumor invasion. Pericardial LGE is important for differentiation from constrictive pericarditis: in constrictive pericarditis LGE is diffuse/thin linear, while in mesothelioma it is nodular/massive/heterogeneous.
Report Sentence
On LGE sequences, pericardial masses show intense and heterogeneous late gadolinium enhancement, with abnormal LGE suggesting myocardial invasion observed/not observed in the ___ region.
On FDG PET-CT, pericardial mesothelioma typically shows high FDG uptake (SUVmax typically 5-15). PET-CT is valuable for assessing tumor metabolic activity, monitoring treatment response, and screening for distant metastases. Pericardial involvement extent is better evaluated on PET-CT — low-density or small nodules may be missed on CT but are detected on PET due to their metabolic activity. Metastasis screening: lung, pleura, mediastinum, abdomen — distant metastasis rate is low (20-30%) in pericardial mesothelioma but local invasion is extensive.
Report Sentence
On FDG PET-CT, high metabolic activity is observed along the pericardium (SUVmax: ___), consistent with pericardial malignancy; distant metastasis findings are not observed/are observed.
Criteria
Epithelioid cell predominance. Calretinin, WT-1, cytokeratin 5/6, D2-40 positive (immunohistochemistry). Most common subtype. Differentiation from adenocarcinoma metastasis may be challenging in well-differentiated cases.
Distinct Features
More homogeneous enhancement pattern on imaging, less necrosis compared to other subtypes. Longest median survival (12-18 months). Best response to chemotherapy (cisplatin + pemetrexed) and immunotherapy (anti-PD-1/PD-L1) in this subtype.
Criteria
Spindle cell predominance. Vimentin positive, epithelial markers weak/negative. Most aggressive subtype. Chemotherapy resistant. Differential diagnosis from sarcoma metastasis and fibrosarcoma required.
Distinct Features
On imaging, markedly heterogeneous masses, extensive necrosis, aggressive local invasion (myocardium, lung, mediastinum). Shortest median survival (4-6 months). Treatment options limited — very low response to conventional chemotherapy.
Criteria
Both epithelioid and sarcomatoid components coexist. Each component at least 10%. Prognosis depends on sarcomatoid component ratio — higher sarcomatoid ratio indicates worse prognosis.
Distinct Features
On imaging, heterogeneous masses — different components may show different enhancement patterns. Prognosis between epithelioid and sarcomatoid (median survival 8-12 months). Adequate tissue sampling on biopsy is critical — small biopsy may show only one component and subtype may be misclassified.
Distinguishing Feature
Constrictive pericarditis shows homogeneous/diffuse pericardial thickening, calcification is common (30-50%), effusion usually absent (except effusive-constrictive type), enhancement is minimal/homogeneous. Mesothelioma shows nodular/irregular thickening, calcification rare, hemorrhagic effusion common, intense/irregular enhancement.
Distinguishing Feature
Pericardial metastasis usually develops on the background of known primary malignancy (lung, breast, lymphoma, melanoma). Focal pericardial nodules are more common, diffuse encasement is less frequent. Accompanying lung/mediastinal metastases support the diagnosis. In primary mesothelioma, no known malignancy exists and diffuse pericardial spread is more prominent.
Distinguishing Feature
Benign pericardial effusion is low-density (0-15 HU) transudate without pericardial thickening or nodularity. Hemorrhagic effusion (>25 HU) suggests malignancy, uremia, or anticoagulant use. In mesothelioma, effusion + nodular thickening + enhancement coexist.
Distinguishing Feature
Pericardial lymphoma is usually seen as pericardial involvement of systemic lymphoma — mediastinal/axillary LAP, splenic involvement accompany. Isolated pericardial lymphoma is very rare. Shows homogeneous enhancement and diffusion restriction. On biopsy, lymphoid markers (CD20, CD3) positive, mesothelial markers (calretinin, WT-1) negative.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
3-monthHistopathological confirmation is mandatory for pericardial mesothelioma diagnosis — diagnosis is made by pericardial fluid cytology (50% positivity rate) or pericardial biopsy (open surgical or video-assisted thoracoscopic surgery — VATS). Treatment approach is multidisciplinary: surgery (radical pericardiectomy + tumor debulking), chemotherapy (cisplatin + pemetrexed — pleural mesothelioma regimen applied), radiotherapy (limited efficacy), and immunotherapy (anti-PD-1/PD-L1 — promising in recent studies). Curative surgery is rarely possible because diffuse pericardial involvement and local invasion are usually present at diagnosis. Palliative approaches: pericardial window or pericardiocentesis for recurrent effusion, tamponade prevention. Prognosis is poor — median survival 6-12 months (slightly better in epithelioid subtype). Follow-up with CT or MRI at 3-month intervals. Clinical trial participation should be recommended.
Primary pericardial mesothelioma is an extremely rare and aggressive malignant tumor with a poor prognosis. Median survival is 6-12 months. Early diagnosis is challenging as symptoms are nonspecific and patients often present with pericardial effusion or tamponade. On imaging, when nodular pericardial thickening and hemorrhagic effusion are present, mesothelioma should be considered in the differential. Definitive diagnosis requires pericardioscopic or surgical biopsy. Treatment requires a multimodal approach but outcomes remain limited.